Tumor-Derived cGAMP Regulates Activation of the Vasculature
Marco Campisi(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Ryohei Yoshida(Asahikawa Medical University), Sarah E. Shelton(Massachusetts Institute of Technology), Valeria Chiono(Politecnico di Torino), Tetsuo Tani(Keio University), Tatsuya Osaki(Whitehead Institute for Biomedical Research), Shriram K. Sundararaman(Beth Israel Deaconess Medical Center), Brandon Piel(Dana-Farber Cancer Institute), Sharon Wei Ling Lee(Agency for Science, Technology and Research), Cloud P. Paweletz(Massachusetts General Hospital), Shunsuke Kitajima(Japanese Foundation For Cancer Research), Tran C. Thai(Dana-Farber Cancer Institute), Elena V. Ivanova(Massachusetts General Hospital), Sean Gilhooley(Dana-Farber Cancer Institute), Navin R. Mahadevan(Brigham and Women's Hospital), Israel Cañadas(Fox Chase Cancer Center), Erik H. Knelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Roger D. Kamm(Massachusetts Institute of Technology), Saemi Han(Dana-Farber Cancer Institute)
Cited by 61
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2016|843